- Home
- CYTK vs ELP Comparison
CYTK vs ELP Comparison
Compare CYTK & ELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYTK
- ELP
- Stock Information
- Founded
- CYTK 1997
- ELP 1954
- Country
- CYTK United States
- ELP Brazil
- Employees
- CYTK N/A
- ELP N/A
- Industry
- CYTK Biotechnology: Pharmaceutical Preparations
- ELP Electric Utilities: Central
- Sector
- CYTK Health Care
- ELP Utilities
- Exchange
- CYTK Nasdaq
- ELP Nasdaq
- Market Cap
- CYTK 5.0B
- ELP 5.5B
- IPO Year
- CYTK 2004
- ELP 1997
- Fundamental
- Price
- CYTK $50.26
- ELP $7.11
- Analyst Decision
- CYTK Strong Buy
- ELP
- Analyst Count
- CYTK 17
- ELP 0
- Target Price
- CYTK $82.00
- ELP N/A
- AVG Volume (30 Days)
- CYTK 1.9M
- ELP 234.3K
- Earning Date
- CYTK 02-27-2025
- ELP 02-27-2025
- Dividend Yield
- CYTK N/A
- ELP 4.22%
- EPS Growth
- CYTK N/A
- ELP 43.89
- EPS
- CYTK N/A
- ELP 0.19
- Revenue
- CYTK $3,219,000.00
- ELP $4,076,906,276.00
- Revenue This Year
- CYTK N/A
- ELP N/A
- Revenue Next Year
- CYTK $754.18
- ELP $9.40
- P/E Ratio
- CYTK N/A
- ELP $8.95
- Revenue Growth
- CYTK N/A
- ELP 4.83
- 52 Week Low
- CYTK $40.53
- ELP $5.72
- 52 Week High
- CYTK $81.36
- ELP $8.34
- Technical
- Relative Strength Index (RSI)
- CYTK 58.40
- ELP 64.20
- Support Level
- CYTK $45.05
- ELP $7.05
- Resistance Level
- CYTK $48.30
- ELP $7.31
- Average True Range (ATR)
- CYTK 2.80
- ELP 0.13
- MACD
- CYTK 0.61
- ELP 0.02
- Stochastic Oscillator
- CYTK 86.80
- ELP 68.94
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
About ELP Companhia Paranaense de Energia (COPEL) (each representing one Unit consisting one Common Share and four non-voting Class B Preferred Shares)
Cia Paranaense De Energia Copel is engaged in the areas of generation, transmission, commercialization and distribution of energy. It operates a comprehensive and effective electrical system with its own generating plants, transmission lines, substations, electrical lines and grids of the distribution system. The company's reportable segments include Power generation and transmission, Power distribution, GAS, Power sale, Holding and Services. Majority of its revenue is generated from the Power generation and transmission segment under which it produces electricity from hydraulic, wind, and thermal projects and provides services of transmission and transformation of electric power and other related services.